Aurobindo receives FDA OK for 2 generics

Aurobindo has obtained the Food and Drug Administration’s nod for two generics.

The FDA has approved diclofenac sodium topical solution, 2% w/w, which is the generic of Horizon Therapeutics’ Penn said.

Diclofenac sodium topical solution is indicated for the treatment of the pain of osteoarthritis of the knee(s).

The medication has a market value of $368 million for the 12 months ending February 2023, according to IQVIA.

[Read more: Aurobindo receives FDA approval for 3 generics]

Aurobindo also has received the FDA’s permission for propafenone hydrochloride ER capsules, 225 mg, 325 mg and 425 mg, the generic of GlaxoSmithKline’s Rythmol SR tablets.

Propafenone hydrochloride ER capsules are indicated to prolong the recurrence of symptomatic atrial fibrillation in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease.

The medication has a market value of roughly $18.4 million for the 12 months ending February 2023, according to IQVIA.

[Read more: Aurobindo obtains FDA OK for 2 generics]